#55 of 100 - Pepticom
Updated: Feb 3, 2021
No. 55 of #100israelistartups is Pepticom.
As we have all seen over the past year, the speed at which new drugs can be discovered and developed can have a fundamental impact on the entire human race.
The pharma industry has recently shown an increased interest in peptide research and development, leading to a resurgence of peptide drug candidates. However, the process of discovering new peptides with lifesaving potential is still costly and time consuming.
Israeli start-up, Pepticom is at the forefront of using AI to revolutionize the drug discovery field, both in terms of significantly reducing development timescales and dramatically reducing drug development costs.
Pepticom’s breakthrough technological platform, marrying AI to pharma and biology, is a unique and groundbreaking approach to drug discovery. Optimizing drug discovery means shifting the weight of the discovery effort, allowing an accelerated search of the entire realm of possible solutions.
The Jerusalem-based company's technology significantly accelerates the ability of researchers to discover advanced peptide-based drug candidates. Peptides are used in various therapies, and are recognized for being highly selective and efficacious as well as relatively safe. Pepticom’s AI, technology enables the discovery of the most advanced peptide-based drug candidates by searching an enormous set of possible solutions, vastly reducing the risk of failure during development.
AI learning helps implement the right conclusions towards finding the optimal peptides for target binding. Pepticom designs novel peptide drug candidates to optimize the discovery process, accelerate time to market and reduce development risks and costs
The Technology Behind Pepticom
Pepticom has introduced “Swarm Intelligence 2.0”, in which various bots are able to sense, interact and coordinate a collective intelligence with the addition of evolutionary mechanism of bot-selection.
Utilizing AI-driven reinforcement learning, search algorithms, smart grids and scoring functions allows Pepticom to discover better binding peptides at each learning iteration.
Immanuel Lerner, Co-Founder & CEO told us:
"Pepticom already improves discovery time by almost a year, and we are working towards further reduction in that time and thus significantly improve drug time to market. Our mission is to advance 21st century medicine by improving access to novel peptide therapeutics. Our technology allows us to harnass the power of AI to design the best peptide drugs possible by expanding the exploration process to uncharted chemical space."
2Scots is delighted to support Pepticom as part of our #100israelistartups initiative and wish Immanuel, Maayan and all the team huge success as they revolutionize drug discovery for generations to come.